CHU Dinant-Godinne
Yvoir, 5530, Belgium
NCT Number: NCT02221141
The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.
Actually the early diagnosis is important because a treatment exists that can prevent future complications.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Yvoir, 5530, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 day
Laurence Gabriel
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05730309
Cardiomegaly, Cardiovascular Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05179668
Cardiomegaly, Cardiovascular Diseases
Feldbach, Austria
View Trial DetailsNCT03816462
Body Weight, Cardiomegaly
Baltimore, Maryland, United States
View Trial DetailsNCT05646056
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Jacksonville, Florida, United States
View Trial Details